Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports is a research paper published in Frontiers in Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: UH2 CA206126
NCI NIH HHS
Grant: R21 CA239052
NCI NIH HHS
Grant: U01 CA233370
NCATS NIH HHS
Grant: UH3 TR000923
NCI NIH HHS
Grant: UH3 CA206126
National Institutes of Health
Grant: 1R21CA239052-01
Ultra-short circulating tumor DNA (uctDNA) for liquid biopsy of non-small cell lung cancer
National Institutes of Health
Grant: 5UH3TR000923-04
Clinical Utility of Salivary ExRNA Biomarkers for Gastric Cancer Detection
National Institutes of Health
Grant: 5UH2CA206126-02
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients
National Institutes of Health
Grant: 5U01CA233370-03
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer
National Institutes of Health
NIH Clinical Center
FWCI
0.57
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals